These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27765854)

  • 41. Evaluation of Anti-Metastatic Potential of the Combination of Fisetin with Paclitaxel on A549 Non-Small Cell Lung Cancer Cells.
    Klimaszewska-Wiśniewska A; Hałas-Wiśniewska M; Grzanka A; Grzanka D
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
    Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
    Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
    Lin MT; Lin CL; Lin TY; Cheng CW; Yang SF; Lin CL; Wu CC; Hsieh YH; Tsai JP
    Tumour Biol; 2016 May; 37(5):6987-96. PubMed ID: 26662956
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
    Toner AP; McLaughlin F; Giles FJ; Sullivan FJ; O'Connell E; Carleton LA; Breen L; Dunne G; Gorman AM; Lewis JD; Glynn SA
    Br J Cancer; 2013 Oct; 109(8):2131-41. PubMed ID: 24052043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
    Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells.
    Mang J; Merkle K; Heller M; Schüler J; Tolstov Y; Li J; Hohenfellner M; Duensing S
    Urol Oncol; 2017 Jan; 35(1):32.e9-32.e16. PubMed ID: 27692847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p-STAT3 in prostate cancer.
    Wang L; Lyu C; Stadlbauer B; Buchner A; Nößner E; Pohla H
    Prostate; 2024 Feb; 84(2):131-147. PubMed ID: 37828768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-EGFR immunoliposomes for cabazitaxel delivery: From formulation development to in vivo evaluation in prostate cancer xenograft model.
    Carolina Cruz de Sousa A; da Silva Santos E; da Silva Moreira T; Gabriela Araújo Mendes M; Rodrigues Arruda B; de Jesus Guimarães C; de Brito Vieira Neto J; Santiago de Oliveira Y; Pedro Ayala A; Rodrigues da Costa MD; Lima Sampaio T; Paula Negreiros Nunes Alves A; Pessoa C; Petrilli R; Eloy JO
    Int J Pharm; 2024 Aug; 661():124439. PubMed ID: 38972520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
    Dalrymple SL; Becker RE; Isaacs JT
    Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy.
    Sundaram S; Durairaj C; Kadam R; Kompella UB
    Mol Cancer Ther; 2009 Jun; 8(6):1655-65. PubMed ID: 19509261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.
    Hoang B; Ernsting MJ; Tang WS; Bteich J; Undzys E; Kiyota T; Li SD
    Cancer Lett; 2017 Dec; 410():169-179. PubMed ID: 28965854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.
    Sémiond D; Sidhu SS; Bissery MC; Vrignaud P
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):515-28. PubMed ID: 23820961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
    Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
    Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
    Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
    Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The synergistic anticancer effect of salinomycin combined with cabazitaxel in CD44+ prostate cancer cells by downregulating wnt, NF-κB and AKT signaling.
    Erdogan S; Serttas R; Turkekul K; Dibirdik I
    Mol Biol Rep; 2022 Jun; 49(6):4873-4884. PubMed ID: 35705771
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
    Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
    Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo.
    Gonzalez-Moreno O; Segura V; Serrano D; Nguewa P; de las Rivas J; Calvo A
    Int J Cancer; 2007 Sep; 121(6):1197-204. PubMed ID: 17520673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
    Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
    Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
    Rahman KM; Banerjee S; Ali S; Ahmad A; Wang Z; Kong D; Sakr WA
    Cancer Res; 2009 May; 69(10):4468-75. PubMed ID: 19435906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.